文献速递睡眠呼吸障碍

CPAP治疗中新发中枢性睡眠呼吸暂停的轨迹分析

Trajectories of Emergent Central Sleep Apnea During CPAP Therapy.
PubMed 文献 · Chest · 2017-06-16

本研究基于美国远程监测设备数据,分析133,006例使用CPAP≥90天的阻塞性睡眠呼吸暂停患者,根据第1周和第13周中枢呼吸暂停指数(CAI)将中枢性睡眠呼吸暂停(CSA)分为持续、短暂和新发三类。结果显示3.5%患者存在CSA,其中新发占19.7%,新发CSA与年龄较大、残余AHI和CAI较高及漏气较多相关,且治疗终止风险更高。

要点

  • CPAP治疗中约3.5%患者出现CSA,新发CSA占19.7%。
  • 新发CSA患者第13周残余AHI和CAI更高,漏气更多。
  • 出现新发CSA的患者治疗终止风险显著增高。

核心结论

  • CPAP治疗期间中枢性睡眠呼吸暂停存在短暂、持续和新发等多种轨迹,新发CSA与治疗终止风险升高相关。

研究设计与样本

  • 基于美国远程监测设备数据的回顾性分析,纳入133,006例使用CPAP≥90天且第1周和第13周均有≥1天使用≥1小时的患者。

主要发现

  • 第1周或第13周存在CSA的患者比例为3.5%,其中短暂、持续和新发CSA分别占55.1%、25.2%和19.7%。
  • 与无新发CSA患者相比,新发CSA患者年龄更大、第13周残余AHI和CAI更高、漏气更多(均P < .001)。
  • 出现任何新发CSA的患者治疗终止风险均高于未出现CSA者(均P < .001)。

关键数值与推荐

  • 阻塞性睡眠呼吸暂停:第1周平均CAI < 5/h且第13周 < 5/h。
  • 短暂CSA:第1周CAI ≥ 5/h且第13周 < 5/h。
  • 持续CSA:第1周CAI ≥ 5/h且第13周 ≥ 5/h。
  • 新发CSA:第1周CAI < 5/h且第13周 ≥ 5/h。

临床怎么用

  • 可通过远程监测识别CPAP治疗中新发CSA,便于早期干预以降低治疗终止风险并转向更有效的通气模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The emergence of central sleep apnea (CSA) during positive airway pressure (PAP) therapy has been observed clinically in approximately 10% of obstructive sleep apnea titration studies. This study assessed a PAP database to investigate trajectories of treatment-emergent CSA during continuous PAP (CPAP) therapy. METHODS: U.S. telemonitoring device data were analyzed for the presence/absence of emergent CSA at baseline (week 1) and week 13. Defined groups were as follows: obstructive sleep apnea (average central apnea index [CAI] < 5/h in week 1, < 5/h in week 13); transient CSA (CAI ≥ 5/h in week 1, < 5/h in week 13); persistent CSA (CAI ≥ 5/h in week 1, ≥ 5/h in week 13); emergent CSA (CAI < 5/h in week 1, ≥ 5/h in week 13). RESULTS: Patients (133,006) used CPAP for ≥ 90 days and had ≥ 1 day with use of ≥ 1 h in week 1 and week 13. The proportion of patients with CSA in week 1 or week 13 was 3.5%; of these, CSA was transient, persistent, or emergent in 55.1%, 25.2%, and 19.7%, respectively. Patients with vs without treatment-emergent CSA were older, had higher residual apnea-hypopnea index and CAI at week 13, and more leaks (all P < .001). Patients with any treatment-emergent CSA were at higher risk of therapy termination vs those who did not develop CSA (all P < .001). CONCLUSIONS: Our study identified a variety of CSA trajectories during CPAP therapy, identifying several different clinical phenotypes. Identification of treatment-emergent CSA by telemonitoring could facilitate early intervention to reduce the risk of therapy discontinuation and shift to more efficient ventilator modalities.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Liu D, Armitstead J, Benjafield A, et al. Trajectories of Emergent Central Sleep Apnea During CPAP Therapy. Chest. 2017. PMID: 28629918. doi:10.1016/j.chest.2017.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。